产品展示
PRODUCTS
Check category

Recombinant human nerve growth factor injection approved for clinical trial
Top

  • Categories:Corporate news
  • Author:
  • Origin:
  • Time of issue:2018-11-28 19:15
  • Views:

Recombinant human nerve growth factor injection approved for clinical trial
Top

(Summary description)
  On November 28, 2018, the class 1 new biological drug "recombinant human nerve growth factor injection" developed by our company obtained the clinical trial approval document issued by the State Drug Administration.

  • Categories:Corporate news
  • Author:
  • Origin:
  • Time of issue:2018-11-28 19:15
  • Views:
Information

  On November 28, 2018, the class 1 new biological drug "recombinant human nerve growth factor injection" developed by our company obtained the clinical trial approval document issued by the State Drug Administration.

Quick navigation

Home  丨  About us  丨  R & D platform  丨  Product  丨  Contact us

Contact us

 

Address: Building 7, Kangyuan medical science and Technology Park, 578 longmian Avenue, Jiangning District, Nanjing City, Jiangsu Province
Postal Code: 211100
Contact information: 025-58310595 (switchboard)
Fax: 025-58310595-108

 

江苏中新医药有限公司

Scan

Copyright © 2021 Jiangsu Zhongxin Pharmaceutical Co., Ltd    苏ICP备11074983号-1          Powered by:www.300.cn